Citi Maintains a 'Buy' on SenoRx Inc (SENO); First Look – Weak 1Q10 Overshadowed by BCR Acquisition
SENO Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 7 | New: 15
Citi maintains a 'Buy' on SenoRx Inc (Nasdaq: SENO), price target $10.
Citi analyst says, "This was a weak quarter for SENO as fewer patient visits for mammography in the market translated to fewer biopsy procedures. In addition, Contura adoption has slowed considerably with revs down 22% Q/Q. Mgmt attributed the Contura weakness to the recent ASTRO guidelines for APBI (accelerated partial breast irradiation), but we think Hologic's (Nasdaq: HOLX) recent Mammosite MLB launch, competitor pricing pressure, and lack of physician acceptance for the procedure also played important roles. We don’t believe these issues will abate in the near term, but they are clearly overshadowed now that C.R. Bard (NYSE: BCR) is set to acquire SENO for $11 in cash."
To see all the upgrades/downgrades on shares of SENO, visit our Analyst Ratings page.
SenoRx, Inc. develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer.
Citi analyst says, "This was a weak quarter for SENO as fewer patient visits for mammography in the market translated to fewer biopsy procedures. In addition, Contura adoption has slowed considerably with revs down 22% Q/Q. Mgmt attributed the Contura weakness to the recent ASTRO guidelines for APBI (accelerated partial breast irradiation), but we think Hologic's (Nasdaq: HOLX) recent Mammosite MLB launch, competitor pricing pressure, and lack of physician acceptance for the procedure also played important roles. We don’t believe these issues will abate in the near term, but they are clearly overshadowed now that C.R. Bard (NYSE: BCR) is set to acquire SENO for $11 in cash."
To see all the upgrades/downgrades on shares of SENO, visit our Analyst Ratings page.
SenoRx, Inc. develops, manufactures and sells medical devices that are used in the diagnosis and treatment of breast cancer.
You May Also Be Interested In
- UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
- Nomura Securities Maintains a 'Buy' on Lowe's (LOW); Review of Q1
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
